NCT00575094View on ClinicalTrials.gov

Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Community-Acquired Infections
Interventions
DRUG

tigecycline

Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days

Trial Locations (9)

471-8513

Toyota-shi

830-8543

Kurume-shi

832-0059

Yanagawa-shi

070-8644

Asahikawa-shi

319-1113

Funaishikawa

230-0012

Yokohama

236-0051

Yokohama

392-8510

Suwa-shi

204-8585

Kiyose-shi

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00575094 - Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects | Biotech Hunter | Biotech Hunter